Mary Caffrey

Frank Martin, PhD, director of research at JDRF, discusses the organization's efforts to educate regulators about the disease.

Two top cardiologists debated evidence involving one clinical trial for omega-3 fatty acids, with implications for another, the REDUCE-IT study for icosapent ethyl (Vascepa).

The Dapagliflozin in Respiratory Failure in Patients With COVID-19 trial is the first phase 3 study to examine whether this SGLT2 inhibitor, which has proven effective for multiple chronic conditions, might be similarly useful in an acute setting.

The investigational drug for obstructive hypertrophic cardiomyopathy is in front of FDA, with an approval target date of January 28, 2022.

Results presented at the American College of Cardiology's 70th Scientific Session show most patients prefer a smaller dose and are more likely to stick with it.

Fourteen months after the American College of Cardiology (ACC) switched its 17,000-person meeting to a virtual format on short notice, the meeting will be online May 15-17 for the second year. The 70th Scientific Session will feature 25 late-breaking clinical trials, emphasizing treatment of heart failure and the right aspirin dose for prevention of secondary cardiovascular disease.

Frank Martin, PhD, director of research at JDRF, shares feedback from patients on JDRF's T1Detect screening program.

Both studies were featured during the American College of Cardiology's annual briefing on results for consumers. They will be presented during the 70th Scientific Session, which is set for May 15-17, 2021.

Frank Martin, PhD, director of research at JDRF, discusses the importance of diabetic ketoacidosis mitigation efforts and appropriate education for parents of children with type 1 diabetes (T1D).

Tuesday marked the first of 3 days of hearings on whether checkpoint inhibitors should keep indications after follow-up studies failed to show benefits that led to accelerated approval.

Interest in therapies that target DDR genes has increased since 2015, when basic science in this area won the Nobel Prize in Chemistry.

Research published in November found an 85% drop in breast cancer screening and a 75% drop in colon cancer screening. Since that time, screening rates have improved somewhat.

The research, funded in part by the JDRF, springs from the fact that autoimmune diseases are increasing worldwide, and are rising faster among Black and Hispanic youth.

Last year, pemigatinib, the first targeted therapy in cholangiocarcinoma was approved for previously treated patients with FGFR2 fusions or rearrangements.

Authors of a review article explore the role of HLA antigens in type 1 diabetes and autoimmune thyroid disease.

On the first day of the Cholangiocarcinoma Foundation Annual Meeting, Elli Brimble, MS, MSc, Ciitizen’s head of Clinical Operations, offered insights from an ongoing study based on data provided by patients.

The addition of immunotherapy and targeted therapies to the NCCN guidelines in bile duct cancer means that tumor mutation profiling is now called for to guide treatment decisions.

Al B. Benson, MD, FACP, FASCO, professor of medicine and director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center, discusses the potential for neoadjuvant intervention in hepatobiliary cancers.

Updates to the NCCN Guidelines in multiple myeloma reflect recent trial results, giving clinicians and patients many choices.

A panel at the NCCN Virtual Annual Meeting finds that while primary care physicians and oncologists can share information, records may not be well integrated and in easy-to-use formats.

Penn Medicine's Stephen Schuster, MD, offers an overview of an eventful year in CAR T-cell therapy at the NCCN Virtual Annual Meeting.

Pharmacists from the Cleveland Clinic discuss the impact of payer dispensing requirements, known as white bagging and brown bagging, on oncology practices and on patients.

An administrator in the Geisinger Cancer Institute discusses the rollout of ClinicalPath.

A panel at the Association of Community Cancer Centers discusses lessons from the year of COVID-19.

FDA's action marks an abrupt change of course from the Priority Review granted September 2020.

The EMA panel's nod pemigatinib in bile duct cancer is the latest positive news for the targeted therapy after its FDA approval and appearance in the NCCN Guidelines.

Donald M. Berwick, MD, MPP, the former CMS administrator who is president emeritus and senior fellow at the Institute for Healthcare Improvement, discusses cost variation in cancer care found through the digital classification system the COTA Nodal Address.